Clicky

Acura Pharma Cmn(ACUR)

Description: Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.


Keywords: Pharmaceutical Drugs Euphoriants Psychoactive Drugs Chemical Compounds Technology Products Morphinans Platform Technologies Sinus Amphetamine Oxycodone Pseudoephedrine Suse Decongestants Methamphetamine

Home Page: www.acurapharm.com

616 N. North Court
Palatine, IL 60067
United States
Phone: 847 705 7709


Officers

Name Title
Mr. Robert B. Jones CEO, Pres & Director
Mr. Peter A. Clemens Sr. VP, CFO & Sec.
Dr. Albert W. Brzeczko Ph.D. VP of Pharmaceutical Sciences of Acura Pharmaceutical Technologies, Inc.
Mr. Robert A. Seiser CPA, Ph.D. VP, Treasurer & Corp. Controller

Exchange: OTCQB

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 24.1071
Price-to-Sales TTM: 1.4496
IPO Date:
Fiscal Year End: December
Full Time Employees: 12
Back to stocks